Jefferies Group’s Relmada Therapeutics RLMD Stock Holding History

Jefferies Group’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-12,428	Closed	-$335K	–	1803
2022 Q1	$335K	Buy	+12,428	New	+$257K	﹤0.01%	1154

Other funds holding RLMD

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Jefferies Group's RLMD Position: Q2 2022 in Review

Jefferies Group sold out of Relmada Therapeutics (RLMD) in Q2 2022, closing a stake of 12,428 shares — an estimated $335K sold.

Jefferies Group first reported a position in RLMD in Q1 2022 and held it in 1 quarter. The position peaked at $335K in Q1 2022. 113 funds tracked by Wall St. Rank hold RLMD as of Q2 2022.

Jefferies Group reported no remaining Relmada Therapeutics position as of Q2 2022 after selling out during the quarter.
Jefferies Group sold 12,428 Relmada Therapeutics shares in Q2 2022, an estimated $335K.
Jefferies Group first reported a position in Relmada Therapeutics in Q1 2022 and held it in 1 quarter.
Jefferies Group's Relmada Therapeutics position peaked at $335K in Q1 2022.
113 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2022.

Based on Jefferies Group's 13F filing for Q2 2022, filed 15 Aug 2022.